Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMG2SKR)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||
|
|||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Normal (Transformed)
Lung
Lung adenocarcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
